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Gastric cancer can be classified as cardia and non-cardia subtypes according to the
anatomic site. Although the gastric cancer incidence has decreased steadily in several
countries over the past 50 years, the incidence of cardia cancers and esophageal adeno-
carcinoma (EAC) continue to increase. The etiological factors involved in the development
of both cardia cancers and EACs are associated with high animal fat intake, which causes
severe obesity. Central obesity plays roles in cardiac-type mucosa lengthening and partial
hiatus hernia development. There are two distinct etiologies of cardia cancer subtypes:
one associated with gastroesophageal reflux (GER), which predominantly occurs in
patients without Helicobacter pylori (H. pylori) infection and resembles EAC, and the
other associated with H. pylori atrophic gastritis, which resembles non-cardia cancer.
The former can be developed in the environment of high volume duodenal content reflux,
including bile acids and a higher acid production in H. pylori–negative patients. N-nitroso
compounds, which are generated from the refluxate that includes a large volume of bile
acids and are stabilized in the stomach (which has high levels of gastric acid), play a pivotal
role in this carcinogenesis. The latter can be associated with the changing colonization
of H. pylori from the distal to the proximal stomach with atrophic gastritis because a high
concentration of soluble bile acids in an environment of low acid production is likely to
act as a bactericide or chemorepellent for H. pylori in the distal stomach. The manuscript
introduces new insights in causative factors of adenocarcinoma of the cardia about the
role of bile acids in gastro-esophageal refluxate based upon robust evidences supporting
interactions among pH, H. pylori, and bile acids.
Keywords: Helicobacter pylori, cardia gastric adenocarcinoma, gastroesophageal reflux disease, bile acids, pH,
atrophic gastritis
Introduction
Gastric cancer is the sixth most common type of cancer and the fourth most common cause of
cancer-related deaths worldwide (Ferlay et al., 2013). Gastric cancer can be classified according to the
anatomic site as cardia (the upper part of the stomach adjoining the esophagus) and non-cardia (the
mid and distal stomach) subtypes. Although the incidence of gastric cancer has steadily declined in
several countries over the past 50 years, the overall decline is opposite to the subsite-specific increase
in cardia cancers (Chow et al., 1998b; Carr et al., 2013). The increase in incidence is approximately
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seven fold, a more substantial increase than that in several other
malignancies (Carr et al., 2013). Potential differences in the pre-
sentation and outcome of patients with gastric cardia or non-
cardia adenocarcinoma may exist (Shi et al., 2011). Although it
has been reported that cardia cancers may be related to gastroe-
sophageal reflux (GER) similar to esophageal adenocarcinoma
(EAC), the etiology of adenocarcinoma of the cardia remains
unclear and controversial (Ye et al., 2001).
It is widely accepted that chronic mucosal inflammation causes
themajority of gastric cancers due toHelicobacter pylori (H. pylori)
infection (International Agency for Research on Cancer, 1994).
However, the roles of H. pylori infection in the development of
cardia cancer are contradictory (Chow et al., 1998a; Eslick et al.,
1999; Ekstrom et al., 2001; Helicobacter and Cancer Collabora-
tive Group, 2001; Limburg et al., 2001; Kamangar et al., 2006,
2007). Several studies indicate two distinct etiologies of cardia
cancer: one that is more commonly associated with GER in H.
pylori–negative than in H. pylori–positive patients and resembles
EAC; and the other that is associated with H. pylori atrophic
gastritis and resembles non-cardia cancer (McColl, 2006; Hansen
et al., 2007; Derakhshan et al., 2008). In this manuscript, we try
to explain the potential mechanisms involved in the development
of gastric cardia adenocarcinoma with two distinct etiologies by
elucidating the interaction among pH, H. pylori, and bile acids.
Cardia Adenocarcinoma Associated with
GER Resembling EAC
Here we attempt to explain the possible mechanism involved in
the development of cardia adenocarcinoma associated with GER
by considering the causative factors of EAC.
Gastroesophageal Reflux Disease and Barrett
Esophagus: Major Risk Factors for EAC
Most cases of esophageal cancer arise as squamous cell carci-
noma or adenocarcinoma. Forty years ago, approximately 75%
of diagnosed esophageal cancer cases, even those in the United
States (U.S.), were esophageal squamous cell carcinoma and the
remaining 25% were EAC. Among Caucasian men, the incidence
of EAC has increased since the mid-1970s, and EAC has become
the leading type of esophageal cancer, representing 80% of cases
(Devesa et al., 1998; Enzinger and Mayer, 2003; Absi et al., 2013).
Gastroesophageal reflux disease (GERD) and Barrett esopha-
gus are major risk factors for EAC, the risk for which increases
with the frequency and duration of reflux symptoms (Lagergren
et al., 1999; Wu et al., 2003; Anandasabapathy et al., 2007). Fre-
quent reflux of the gastric juices, which contain acid, pepsin, and
bile, is thought to induce Barrett esophagus, a condition of colum-
nar metaplasia of the esophageal squamous epithelium damaged
by GER (Souza et al., 2002; Theisen et al., 2005; Spechler and
Souza, 2014). U.S. gastroenterology societies require esophageal
biopsies to show intestinal metaplasia with goblet cells for the
definitive diagnosis of Barrett esophagus (Wang and Sampliner,
2008; Spechler et al., 2011; ASGEStandards of PracticeCommittee
et al., 2012). It has been widely accepted that an intestinal-type
mucosa is the precursor of EAC (Ruol et al., 2000). However, it
has been recently accepted that a cardiac-type mucosa without
the intestinal goblet cells background of EAC is also occasionally
encountered (Takubo et al., 2005, 2009; Kushima et al., 2013).
Roles of Central Obesity in Cardiac-type Mucosa
Lengthening and Partial Hiatus Hernia
Development
Abdominal obesity promotes GERD by elevating intra-abdominal
pressure, which produces a hiatus hernia (El-Serag, 2008). Stud-
ies comparing computed tomography–measured abdominal fat
composition showed that a large amount of visceral abdominal
fat relative to subcutaneous fat is associated with a significant
increase in the risk of Barrett esophagus (El-Serag et al., 2014).
A recent study of 24 healthy H. pylori–negative volunteers with a
small waist circumference and 27 with a large waist circumference
reported that central obesity is associatedwith the intrasphincteric
extension of gastric acid, allowing it to move proximally within
the intrasphincteric reflux, and cardiac-typemucosal lengthening,
which predisposes subjects to cardia adenocarcinoma (Robertson
et al., 2013). Furthermore, according to a recent study of healthy
volunteers without a history of GERD, central obesity and the use
of a waist belt can produce a partial hiatus hernia and contribute
to excess acid exposure of the distal esophageal mucosa, leading
to metaplastic columnar changes (Lee et al., 2014).
Role of High Animal Fat Intake in EAC
Development
A high fat intake, which can be a cause of central obesity, plays a
role in an increased risk ofGERD symptoms and erosive esophagi-
tis, which are risk factors for EAC (El-Serag et al., 2005). The
mechanism underlying this effect remains unclear; however, it
may be proven by the increasing rates of GERD in theU.S. because
the fat content of its food supply has increased by 38% between
1909 and 1988 (Raper et al., 1992). To examine the roles of high
animal fat intake in the etiology of EAC, we fed a high animal fat
diet to rats with reflux of the duodenal contents (Chen et al., 2007).
First, Wistar rats in the control group were fed a low soybean
oil diet and the other rats in the high-fat group were fed a high
cow fat diet. The resulting morphological changes between these
groups were then evaluated up to 30 weeks after surgery. The
rats with reflux of the duodenal contents in the high-fat group
showed a significantly higher incidence of Barrett esophagus and
Barrett dysplasia than those in the control group. In addition, the
incidence of EAC in the high-fat group was also slightly higher
than that in the control group (Chen et al., 2007). These findings
suggest that a high animal fat intake plays a pivotal role in EAC.
In the clinical setting, it has been reported that high-fat dairy is
associated with an increased risk of EAC (Navarro Silvera et al.,
2008).
High Dietary Animal Fat Changes the Bile Acid
Composition
We compared the total level and composition of bile acids in the
bile juice collected from the common bile ducts of rats that had
not undergone surgery (Chen et al., 2007). The bile juice was aspi-
rated after the animals had been fed different diets for 1 month,
and the bile acid concentrations were measured. High dietary
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animal fat changed the bile acid composition and increased the
concentration of taurine conjugates in the bile juice (Chen et al.,
2007). The chemical characteristics of bile in humans are governed
by the pKa of the individual bile acids. Free bile acids have a
pKa of approximately 7 and comprise approximately 2% of the
bile. Glycine-conjugated bile acids have a pKa of 4.3–5.2 and
comprise >60% of the bile, while taurine-conjugated bile acids
have a pKa of 1.8–1.9 and comprise 20% of the bile, resulting
in a ratio of glycine to taurine conjugates of approximately 3:1
(Nair and Kritchenvski, 1971; Stamp, 2002). Because only taurine
conjugates are soluble among various bile acids in humans with
intact gastric acid production and can affect the epithelium, an
increase in taurine-conjugated bile acids in the refluxate under
acidic conditions may play a role in Barrett carcinogenesis and
cancer progression.
In a study examining bile acid, the esophageal samples taken
from 10 asymptomatic subjects and 30 patients with GERD
symptomswere analyzed usingmodified high-performance liquid
chromatography (Nehra et al., 1999). There was a significantly
greater proportion of secondary bile acids, deoxycholic acids,
and taurodeoxycholic acids in patients with erosive esophagi-
tis and Barrett esophagus/stricture. Taurocholic acid was also
significantly increased in the Barrett esophagus/stricture group
compared with the minimal injury group (Nehra et al., 1999).
The study concluded that mixed reflux is more harmful than acid
reflux alone and that possible toxic synergism exists between the
taurine conjugates and the acid (Nehra et al., 1999). These findings
are consistent with those of our animal experiments mentioned
above.
Endogenous DNA Adducts and N-nitroso Bile
acids
To explore the causative factors of EAC, thiazolidine-4-carboxylic
acid (thioproline) was administered as a nitrite scavenger to rats
considered the gastroduodenal contents reflux model (Kumagai
et al., 2004). Postoperatively, we divided the reflux animals into
two diet groups. Animals in the control groupwere given a normal
diet, while the thioproline group was given food containing 0.5%
thioproline. All esophageal sections in both groups were histolog-
ically evaluated. EAC developed in 38.9% of the control group,
whereas no EAC was detected in the thioproline group (Fisher
exact test, P < 0.05). We then proposed that nitroso compounds
derived from duodenal contents reflux play a crucial role in the
development of EAC (Kumagai et al., 2004). We also performed a
similar experiment using the rat duodenal contents reflux model
for gastric carcinogenesis. This study also suggested a connection
between nitroso compounds and gastric carcinogenesis (Suo et al.,
2006). Furthermore, Terasaki et al. (2008) detected the endoge-
nous DNA adducts produced fromN-nitroso bile acid conjugates,
such asN-nitrosoglycocholic acid andN-nitrosotaurocholic acid,
in the glandular stomach of the duodenal contents reflux rats.
These observations confirmed thatN-nitrosotaurocholic acid and
N-nitrosoglycocholic acid are formed by the nitrosation of gly-
cocholic acid and taurocholic acid, respectively. These studies
suggest that nitrosated bile acid conjugates, which have muta-
genicity, could contribute to the development of both EAC and
gastric carcinogenesis.
Highly Acidic Condition Stabilizes Mutagenic
N-nitroso Bile Acids
The pathogenesis of GERD is multifactorial since it involves tran-
sient lower esophageal sphincter relaxation as well as other lower
esophageal sphincter pressure abnormalities (Castell et al., 2004).
GERD is a complex problem caused by many factors that are
exacerbated when the patient is in the supine position (Castell
et al., 2004). Gastric contents are easily pooled, and N-nitroso
compounds could be generated at night, in the gastric juice with
the refluxate including bile acids in the fornix located on the
posterior side of the body. Moreover, both the esophagus and
the proximal cardia portion are easily exposed to the N-nitroso
compounds by transient lower esophageal sphincter relaxation as
well as other lower esophageal sphincter pressure abnormalities
in the supine position (Macke et al., 2011). We reported that
one of these nitroso compounds, N-nitroso glycocholic, rapidly
decomposed under alkaline conditions (pH 9) [t(1=2) = 0.96 h]
but remained quite stable under acidic (pH 2) [t(1=2) = 12.8 h]
and neutral (pH 7) [t(1=2) = 7.8 h] conditions (Araki et al.,
2008). These findings suggest that a highly acidic condition also
contributes to carcinogenesis as a stabilizer ofN-nitroso bile acids.
H. pylori Protects Against GERD
There are inverse associations between the presence of H. pylori
(particularly cagA+ strains) and disorders such as GERD, Bar-
rett esophagus, and EAC (Vicari et al., 1998; Peek et al., 1999;
Vaezi et al., 2000; Ye et al., 2004; Islami and Kamangar, 2008),
suggesting a protective role ofH. pylori. One potential mechanism
for this effect could be that H. pylori colonization diminishes
gastric acidity; therefore, during reflux episodes, the highly acidic
refluxate inH. pylori–negative patients may be more damaging to
the esophageal epithelium than the low acidic refluxate from the
stomach with H. pylori–associated atrophic gastritis.
Cardia Adenocarcinoma Associated with
H. pylori Atrophic Gastritis Resembling
Non-cardia Cancer
Here we attempt to explain the possible mechanism of the devel-
opment of cardia adenocarcinoma resembling non-cardia cancer
by considering the interactions among pH, H. pylori, and bile
acids.
Relationship between H. pylori and Non-cardia
Gastric Carcinogenesis
H. pylori generally colonizes to the pyloric antrum and H. pylori
was designated a class I carcinogen by theWorldHealthOrganiza-
tion (International Agency for Research on Cancer, 1994). Thus,
the best-established risk factor for non-cardia gastric cancer is H.
pylori infection (Kamangar et al., 2006; Brenner et al., 2009). How-
ever, H. pylori infection is required for gastric cancer to develop
but not for gastric carcinogenesis. There are several animalmodels
of H. pylori–induced carcinogenesis, but unless the bacteria are
combined with a chemical carcinogen or hypergastrinemia, none
of these models reliably produce a malignancy similar to that
observed in humans (Hagiwara et al., 2011; Hayakawa et al.,
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2013; Tsukamoto et al., 2013; Yu et al., 2014; Graham, 2015). H.
pylori has been shown to promote the production of inflammatory
mediators such as interleukin-1b and tumor necrosis factor-a,
potent suppressors of stomach juice secretion. The increase in
stomach pH may lead to the spread of H. pylori from the antrum
to the corpus, resulting in enhanced inflammation in the mucosa
of the corpus followed by parietal cell destruction and irreversible
hypochlorhydria (Takashima et al., 2001; Peek and Blaser, 2002).
Cardia Adenocarcinoma Associated with H.
pylori Atrophic Gastritis
Although most studies of Western populations found no associa-
tion or an inverse association, few studies of Asian populations
have found a positive association between H. pylori seroposi-
tivity and cardia cancer (Helicobacter and Cancer Collaborative
Group, 2001; Dawsey et al., 2002). Recently, two studies reported
on the origin of gastroesophageal junction adenocarcinoma or
esophagogastric junction, which are similar meaning to cardia
adenocarcinoma. Horii et al. reported that the two distinct types
of cancer of different origin might be mixed in cardia adenocar-
cinoma: Barrett esophageal cancer might be associated with high
gastric acid secretion and reflux of gastric acid into the esophagus,
and cancer resembling distal gastric cancer might be associated
with gastric atrophy and low gastric acid secretion (Horii et al.,
2011). Yamada et al. reported that approximately half of patients
with cardia adenocarcinoma harbor histological gastritis (Yamada
et al., 2014). These findings suggest that a part of cardia ade-
nocarcinoma can be associated with H. pylori atrophic gastritis
resembling non-cardia cancer in especially Asian countries.
Interactions Among Bile Acids, pH, and H. pylori
Mechanism of Duodenal Ulcer Treatment by
Antisecretory Therapy
The combination of a high duodenal acid load and H. pylori
infection is possibly a critical event in the pathogenesis of H.
pylori–related duodenal ulcer disease (Graham and Osato, 2000).
Graham et al. suggested that, because glycine-conjugated bile
acids are precipitated at an acidic pH, H. pylori can survive in
gastric metaplasia and any event that leads to an increase in the
duodenal acid load predisposes patients with H. pylori infection
to duodenal ulcer diseases (Graham et al., 1996). They and other
authors also reported that any condition that reduces the duo-
denal acid load (e.g., antisecretory therapy) allows the bile acids
to remain in the solution, inhibits the growth of H. pylori, and
promotes ulcer healing (Han et al., 1996; Graham and Osato,
2000).
Long-term use of Proton Pump Inhibitors
Exacerbates Corpus Atrophic Gastritis in
H. pylori–positive Patients
H. pylori predominantly colonizes the gastric antrum in subjects
in whom acid production is intact. In contrast, in subjects in
whom acid production is decreased by whatever mechanism,
including the use of proton pump inhibitors (PPIs), H. pylori
colonizes the body of the stomach (Kuipers, 2006). Although
there is no proof that the PPI use increases the risk of gastric
cancer at present, PPI therapy affects the pattern and sever-
ity of H. pylori gastritis and accelerates the process of corpus
gland loss (Kuipers, 2006). We recently proposed the mech-
anism of how the long-term use of PPIs exacerbates corpus
atrophic gastritis in H. pylori–positive patients with GERD
that includes interactions among bile acids, pH, and H. pylori
(Mukaisho et al., 2014; Hagiwara et al., 2015). The original
idea about the mechanism of duodenal ulcer treatment by
antisecretory therapy was proposed in the papers mentioned
above.
Duodenogastric reflux including bile reportedly occurs even in
healthy individuals (Keane et al., 1981; Sonnenberg et al., 1982;
Thompson, 1982; Heading, 1983; Muller-Lissner et al., 1983), and
bile reflux is increased in patients with GERD (Kauer et al., 1997).
Bile acids are significant chemorepellents for the bacillusH. pylori
(Worku et al., 2004). PPIs administration inhibits gastric acid
production and changes the concentration of soluble bile acids in
the stomach. Because taurine conjugates have a pKa of 1.8–1.9 and
glycine conjugates have a pKa of 4.3–5.2, only taurine conjugates
are soluble in an acidic environment. However, glycine conjugates
as well as taurine conjugates become soluble in the presence of
PPIs administration. Because the concentration of soluble bile
acids in patients withGERDon PPI therapy is considerably higher
than that in normal subjectswith intact acid production, especially
in the distal stomach with duodenogastric reflux including bile,
the colonization of H. pylori changes the pattern from antral-
predominant to corpus-predominant (Mukaisho et al., 2014).
Mechanism of Changing Colonization of H. pylori in
Atrophic Gastritis
The similar phenomena may occur in the stomach with H.
pylori–associated atrophic gastritis because this condition induces
an environment of low acid production in the stomach. The high
concentration of soluble bile acids in the environment of low
acid production, especially in the distal stomach, is likely to act
as a bactericide or chemorepellent for H. pylori. In contrast, the
concentration of soluble bile acids in the proximal stomach is less
than that of distal stomach.H. pylorimay then colonize within the
proximal rather than distal stomach.
Furthermore, it has been reported that the development of
atrophic gastritis late in life diminishes or eliminates H. pylori
colonization (Karnes et al., 1991). Potential reasons for the specific
association of H. pylori with a normal gastric mucosal epithelium
include a low pH requirement for metabolic processes; depen-
dence on specific nutrients, mucins, or cell-surface components
that are specific features of the gastric epithelium; or the inability
to compete in environments in which other microbes are more
abundant. These findings also might explain the phenomenon
of the changing colonization of H. pylori from the distal to the
proximal stomach.
Summary
Based on anatomic site, gastric cancer can be classified as cardia
or non-cardia subtypes. There are two distinct etiologies of cardia
cancer: one associated with GER and resembles EAC, and the
other associated with H. pylori atrophic gastritis and resembles
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non-cardia cancer. The former can develop in the environment of
high volume duodenal contents reflux, which includes bile acids
and a higher acid production in H. pylori–negative than in H.
pylori–positive patients. The latter can develop because of the
changing colonization ofH. pylori from the distal to the proximal
stomachwith atrophic gastritis in patients withH. pylori infection.
Although the reason for the striking increase in the proportion of
cases of cardia cancer as well as EAC remains unknown, it may
at least partially be explained by increasing rates of GERD, which
induces duodenal contents reflux into the stomach.
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